- Report
- June 2022
- 96 Pages
Global
From €3500EUR$4,210USD£3,140GBP
- Report
- November 2024
- 120 Pages
Global
From €3500EUR$4,210USD£3,140GBP
- Report
- February 2024
- 127 Pages
Global
From €3500EUR$4,210USD£3,140GBP
- Report
- January 2024
- 85 Pages
Global
From €3500EUR$4,210USD£3,140GBP
- Report
- October 2023
- 77 Pages
Global
From €3500EUR$4,210USD£3,140GBP
- Report
- August 2023
- 98 Pages
Global
From €3500EUR$4,210USD£3,140GBP
- Report
- March 2022
- 84 Pages
Global
From €3500EUR$4,210USD£3,140GBP
- Report
- November 2022
- 71 Pages
Global
From €3117EUR$3,500USD£2,701GBP
- Report
- August 2022
- 1834 Pages
Global
From €2226EUR$2,500USD£1,929GBP
- Report
- July 2024
- 132 Pages
Global
From €846EUR$950USD£733GBP
- Newsletter
- July 2025
- 3 Pages
Global
From €117EUR$131USD£101GBP
- Report
- November 2021
- 747 Pages
Global
From €3562EUR$4,000USD£3,087GBP
- Report
- November 2021
- 802 Pages
Global
From €4453EUR$5,000USD£3,859GBP
- Report
- November 2021
- 1184 Pages
Global
From €5343EUR$6,000USD£4,631GBP
- Report
- November 2021
- 1165 Pages
Global
From €5343EUR$6,000USD£4,631GBP
- Book
- November 2024
- 464 Pages
- Book
- March 2024
- 496 Pages

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.
T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more